Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6916248 | 0.82 | CTSL (0.49) | CNR2 | |
| SCHEMBL6803129 | 0.75 | PTPRB (0.52) | CNR2UTS2RCNR1ALDH1A1KDM4E | |
| SCHEMBL2272811 | 0.70 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDMAPK1KDM4E | |
| SCHEMBL6916253 | 0.70 | CA1 (0.44) | ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL19470796 | 0.69 | RAPGEF4 (0.46) | ALDH1A1MAPTHPGDMAPK1KDM4E | |
| SCHEMBL19470800 | 0.67 | RAPGEF4 (0.49) | ALDH1A1MAPTHPGDMAPK1KDM4E | |
| SCHEMBL6956276 | 0.65 | CNR2 (0.65) | CNR2UTS2RCNR1ALDH1A1HPGD | |
| SCHEMBL31302025 | 0.65 | ALDH1A1 (0.54) | ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL28760324 | 0.65 | CNR2 (0.65) | CNR2UTS2RCNR1ALDH1A1HPGD | |
| SCHEMBL27558113 | 0.65 | CNR2 (0.65) | CNR2UTS2RCNR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CNR2 4684/4885UTS2R 2643/4885CNR1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.